Crinetics Pharmaceuticals Inc (CRNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -298,408 | -214,529 | -163,918 | -107,641 | -73,812 |
| Depreciation Amortization | -12,146 | -5,173 | 1,017 | 1,344 | 721 |
| Other Working Capital | 11,635 | 8,044 | 18,612 | 1,096 | 376 |
| Other Operating Activity | 72,949 | 45,351 | 29,084 | 16,613 | 10,688 |
| Operating Cash Flow | $-225,970 | $-166,307 | $-115,205 | $-88,588 | $-62,027 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -570,973 | -195,725 | -172,324 | -56,047 | 403 |
| PPE Investments | -3,844 | -4,688 | -1,656 | -436 | -186 |
| Investing Cash Flow | $-574,817 | $-200,413 | $-173,980 | $-56,483 | $217 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 1,010,435 | 388,944 | 121,963 | 252,679 | 114,571 |
| Financing Cash Flow | $1,010,435 | $388,944 | $121,963 | $252,679 | $114,571 |
| Beginning Cash Position | 56,197 | 33,973 | 201,195 | 93,587 | 40,826 |
| End Cash Position | 265,845 | 56,197 | 33,973 | 201,195 | 93,587 |
| Net Cash Flow | $209,648 | $22,224 | $-167,222 | $107,608 | $52,761 |
| Free Cash Flow | |||||
| Operating Cash Flow | -225,970 | -166,307 | -115,205 | -88,588 | -62,027 |
| Capital Expenditure | -3,844 | -4,688 | -1,656 | -436 | -186 |
| Free Cash Flow | -229,814 | -170,995 | -116,861 | -89,024 | -62,213 |